BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
2 Totsuka M, Honda M, Kanda T, Ishii T, Matsumoto N, Yamana Y, Kaneko T, Mizutani T, Takahashi H, Kumagawa M, Sasaki R, Masuzaki R, Kanezawa S, Nirei K, Yamagami H, Matsuoka S, Ohnishi H, Okamoto H, Moriyama M. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. Intern Med 2021;60:2061-6. [PMID: 33518580 DOI: 10.2169/internalmedicine.6728-20] [Reference Citation Analysis]
3 Ma CD, Imamura M, Talley DC, Rolt A, Xu X, Wang AQ, Le D, Uchida T, Osawa M, Teraoka Y, Li K, Hu X, Park SB, Chalasani N, Irvin PH, Dulcey AE, Southall N, Marugan JJ, Hu Z, Chayama K, Frankowski KJ, Liang TJ. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Nat Microbiol 2020;5:1532-41. [PMID: 32868923 DOI: 10.1038/s41564-020-0781-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Nakamura F, Takeda H, Ueda Y, Takai A, Takahashi K, Eso Y, Arasawa S, Iguchi E, Shimizu T, Mishima M, Kumagai K, Yamashita T, Uemoto S, Kato N, Marusawa H, Sekine A, Seno H. Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing. Sci Rep 2022;12:7083. [PMID: 35490163 DOI: 10.1038/s41598-022-11151-6] [Reference Citation Analysis]
5 Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018;10:E462. [PMID: 30154359 DOI: 10.3390/v10090462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zephyr J, Nageswara Rao D, Vo SV, Henes M, Kosovrasti K, Matthew AN, Hedger AK, Timm J, Chan ET, Ali A, Kurt Yilmaz N, Schiffer CA. Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance. Journal of Molecular Biology 2022. [DOI: 10.1016/j.jmb.2022.167503] [Reference Citation Analysis]
7 AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018;67:1477-92. [PMID: 30215672 DOI: 10.1093/cid/ciy585] [Cited by in Crossref: 277] [Cited by in F6Publishing: 243] [Article Influence: 92.3] [Reference Citation Analysis]
8 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Dultz G, Shimakami T, Schneider M, Murai K, Yamane D, Marion A, Zeitler TM, Stross C, Grimm C, Richter RM, Bäumer K, Yi M, Biondi RM, Zeuzem S, Tampé R, Antes I, Lange CM, Welsch C. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors. J Biol Chem 2020;295:13862-74. [PMID: 32747444 DOI: 10.1074/jbc.RA120.013898] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Malandris K, Kalopitas G, Theocharidou E, Germanidis G. The Role of RASs /RVs in the Current Management of HCV. Viruses 2021;13:2096. [PMID: 34696525 DOI: 10.3390/v13102096] [Reference Citation Analysis]
11 Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt Yilmaz N, Schiffer CA. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir. ACS Chem Biol 2020;15:342-52. [PMID: 31868341 DOI: 10.1021/acschembio.9b00675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
13 de Torres Santos AP, Martins Silva VC, Mendes-Corrêa MC, Lemos MF, de Mello Malta F, Santana RAF, Dastoli GTF, de Castro VFD, Pinho JRR, Moreira RC. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil. Infect Drug Resist 2021;14:723-30. [PMID: 33658809 DOI: 10.2147/IDR.S247071] [Reference Citation Analysis]
14 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]